Evaluation of platelet aggregation and platelet derived microparticles in acute leukemia patients

1. Rassi F El, Arellano M. Update on optimal management of acute myeloid leukemia. Clin Med Insights Oncol. 2013 Aug 12;7:181-97. DOI: 10.4137/CMO.S852810.4137/CMO.S8528374809023997579Search in Google Scholar

2. Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer. 2006 January 30;94(2):200-2. DOI: 10.1038/ sj.bjc.660294510.1038/sj.bjc.6602945236111616421591Search in Google Scholar

3. De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost. 2005 Sep;3(9):1985-92. DOI: 10.1111/j.1538-7836.2005.01467.x10.1111/j.1538-7836.2005.01467.x16102104Search in Google Scholar

4. Falanga A, Marchetti M, Russo L. Venous thromboembolism in the hematologic malignancies. Curr Opin Oncol. 2012 Nov;24(6):702-10. DOI: 10.1097/ CCO.0b013e328359233110.1097/CCO.0b013e328359233123014188Search in Google Scholar

5. Franchini M, Frattini F, Crestani S, Bonfanti C. Bleeding complications in patients with hematologic malignancies. Semin Thromb Hemost. 2013 Feb;39(1):94-100. DOI: 10.1055/s-0032-133115410.1055/s-0032-133115423247655Search in Google Scholar

6. Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009 113(17):3911-17. DOI: 10.1182/ blood-2008-08-17574510.1182/blood-2008-08-175745267312019088376Search in Google Scholar

7. Qian X, Wen-Jun L. Platelet Changes in Acute Leukemia. Cell Biochem Biophys. 2013 Dec;67(3):1473-9. DOI: 10.1007/s12013-013-9648-y10.1007/s12013-013-9648-y23703663Search in Google Scholar

8. Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol. 2009 Mar;22(1):153-63. DOI: 10.1016/j. beha.2008.12.007Search in Google Scholar

9. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009 Aug;102(2):248-57. DOI: 10.1160/TH09-03-019210.1160/TH09-03-019219652875Search in Google Scholar

10. Foss B, Bruserud O. Platelet functions and clinical effects in acute myelogenous leukemia. Thromb Haemost. 2008 Jan;99(1):27-37. DOI: 10.1160/TH07-04-024010.1160/TH07-04-024018217131Search in Google Scholar

11. Cooke NM, Egan K, McFadden S, Grogan L, Breathnach OS, O’Leary J, et al. Increased platelet reactivity in patients with late-stage metastatic cancer. Cancer Med. 2013 August;2(4):564-70. DOI: 10.1002/ cam4.8610.1002/cam4.86379929124156029Search in Google Scholar

12. Costache A, Avram SI, Cernucan A, Barbu D, Angelescu S, Mut Popescu D, et al. What about microparticles? Perspectives and practical aspects. Rev Romana Med Lab. 2013;21(1):9-15. DOI: 10.2478/rrlm-2013-001310.2478/rrlm-2013-0013Search in Google Scholar

13. Auwerda JJ, Yuana Y, Osanto S, de Maat MP, Sonneveld P, Bertina RM, et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011 Jan;105(1):14-20. DOI: 10.1160/TH10-03-018710.1160/TH10-03-0187Search in Google Scholar

14. Lacroix R, Dubois C, Leroyer AS, Sabatier F, Dignat- George F. Revisited role of microparticles in arterial and venous thrombosis. J Thromb Haemost. 2013Jun;11(Suppl 1):24-35. DOI: 10.1111/jth.1226810.1111/jth.12268Search in Google Scholar

15. Bucciarelli P, Martinelli I, Artoni A, Passamonti SM, Previtali E, Merati G et al. Circulating microparticles and risk of venous thromboembolism. Thromb Res. 2012 May;129(5):591-7. DOI: 10.1016/j.thromres.2011.08.02010.1016/j.thromres.2011.08.020Search in Google Scholar

16. Campello E, Spiezia L, Radu CM, Bulato C, Castelli M, Gavasso S et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res. 2011 May;127(5):473-7. DOI: 10.1016/j.thromres.2011.01.00210.1016/j.thromres.2011.01.002Search in Google Scholar

17. Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res. 2010 Sep;126(3):238-42. DOI: 10.1016/j.thromres.2010.06.02510.1016/j.thromres.2010.06.025Search in Google Scholar

18. Tan X, Shi J, Fu Y, Gao C, Yang X, Li J et al. Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. Thromb Haemst. 2013 Jun;109(6):1025-32. DOI: 10.1160/TH12-11-081110.1160/TH12-11-0811Search in Google Scholar

19. Siljander PR. Platelet-derived microparticles - an updated perspective. Thromb Res. 2011 Jan;127(Suppl 2):S30-3. DOI: 10.1016/S0049-3848(10)70152-310.1016/S0049-3848(10)70152-3Search in Google Scholar

20. Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia. Hematology Am Soc Hematol Educ Program. 2007:151-7. DOI: 10.1182/asheducation-2007.1.15110.1182/asheducation-2007.1.15118024623Search in Google Scholar

21. Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica. 2006Nov;91(11):1530-7.Search in Google Scholar

22. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004 Jul;18(3):153-67. DOI: 10.1016/j. tmrv.2004.03.003Search in Google Scholar

23. Psaila B, Bussel JB, Frelinger AL, Michelson AD. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.J Thromb Haemost. 2011 Nov;9(11):2302-10.DOI: 10.1111/j.1538-7836.2011.04506.x10.1111/j.1538-7836.2011.04506.x321001521920014Search in Google Scholar

24. Robier C, Neubauer M, Sternad H, Quehenberger F, Rainer F, Neumeister P. Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry. Thromb Res. 2010 Sep;126(3):232-7.DOI: 10.1016/j.thromres.2010.06.01410.1016/j.thromres.2010.06.01420630570Search in Google Scholar

25. Falanga A, Rickles FR. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies.Hematology Am Soc Hematol Educ Program. 2007:165-71. DOI: 10.1182/asheducation-2007.1.16510.1182/asheducation-2007.1.16518024625Search in Google Scholar

26. Nadir Y, Katz T, Sarig G, Hoffman R, Oliven A, Rowe JM, et al. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologica. 2005Nov;90(11):1549-56.Search in Google Scholar

27. Crespo-Solis E. Thrombosis and acute leukemia. Hematology. 2012 Apr;17(Suppl 1):S169-73. DOI: 10.117 9/102453312X13336169156852 10.1179/102453312X1333616915685222507812Search in Google Scholar